Advertisement

Volume 130, Issue 13

Cover Figure: Novel Fc-engineered CD19 antibody with significant activity. See the article by Schewe et al.

WASHINGTON, September 28, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts
Schewe and colleagues present a novel Fc-engineered CD19 antibody with significant activity in a xenograft model of patient-derived mixed-lineage leukemia (MLL)–rearranged acute lymphoblastic leukemia.

STIM1 and STIM2 cooperatively regulate mouse neutrophil store-operated calcium entry and cytokine production
The investigators identify specific roles of the calcium-sensing molecules STIM1 and STIM2 in calcium-dependent signaling pathways in neutrophils. STIM1 is essential for the regulation of store-operated calcium entry and bactericidal cellular functions such as phagocytosis and degranulation, whereas STIM2 is essential for neutrophil cytokine production.

The promises and challenges of using gene mutations for patient stratification in follicular lymphoma
In a comprehensive Perspective, Weigert and Weinstock review the emerging field of the mutational landscape in follicular lymphoma and discuss how gene mutations can impact risk stratification and predictive biomarker analysis.

Cancer-associated pathways and biomarkers of venous thrombosis
In a review article, Hisada and Mackman examine the mechanisms underlying the strong association of cancer with venous thrombosis and discuss the relevant clinical aspects.

How I treat myeloma with new agents
Moreau discusses current challenges in the treatment of multiple myeloma in the frontline and relapse settings in light of the availability of various novel therapeutic agents.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Jabbour et al report detailed results of a phase 2 randomized study of azacitidine versus decitabine in patients with lower-risk MDS and present favorable response rates, survival data, and cytogenetic responses with both agents.

Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients
These studies demonstrate the feasibility of transduction of Fanconi anemia (FA) progenitor cells with appropriate methods of cell collection and a lentiviral vector, and they establish for the first time a murine xenotransplantation model for human FA stem and progenitor cells with utility for future clinical and translational research.

Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
The second-line therapeutic approach after autologous transplantation in AL amyloidosis is a highly relevant but unsettled clinical topic. This paper offers critical guidance and defines the importance of the timing of second-line therapy after autologous stem cell transplantation.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.